Introduction
Gastric cancer (GC) ranks as the second most frequent cause of cancer-related mortality. 1 In Taiwan, GC results in more than 2000 deaths annually (http://www.mohw.gov. tw/CHT/DOS/Statistic.aspx?f_list_noZ312&fod_list_noZ6 201). The outcome of this common malignancy remains unsatisfactory because of poor understanding of the pathogenesis of GC and the lack of specific target gene therapy. 2, 3 In recent decades, several studies have suggested that genetic alterations may play a role in the development and progression of GC. 4 Studies in molecular pathology, both ours and others, may help clarify the pathogenesis of GC and may reveal useful prognostic molecular markers. 5e10 An elaborate mitochondrial translocation system is necessary to transport protein precursors to their correct intramitochondrial destinations. 11, 12 Cancer cells amplify their capacity for mitochondrial oxidative metabolism and "steal" high-energy mitochondrial fuels from adjacent stromal cells. 13, 14 In direct support of this hypothesis, genetic induction of mitochondrial dysfunction in cancerassociated fibroblasts dramatically promotes both local tumor growth and distant cancer cell metastasis. 15, 16 Translocases of inner mitochondrial membrane (TIMM) family consists of a group of evolutionarily conserved proteins that participate in the import and insertion of multipass transmembrane proteins into the mitochondrial inner membrane. 17 Proteomic analysis showed an increase of TIMM17A protein levels in breast cancer cells, and the increase was validated by immunoblotting and immunohistochemistry. Ductal carcinoma in situ and invasive ductal carcinoma of the breast displayed strong staining, whereas the adjacent normal epithelia and stromal cells displayed negative staining. 18 Similarly, Sotgia et al 19 demonstrated that 15 markers of mitochondrial biogenesis, including TIMM9 and TIMM17A, selectively labeled epithelial breast cancer cells and were largely absent from adjacent tumor stromal cells.
The clinical importance of TIMM family has gained increasing attention in recent years, with reports suggesting that TIMM may contribute to the clinical outcome.
Studies by both Xu et al 18 and Salhab et al 20 have reported that TIMM17A expression was significantly associated with unfavorable pathological parameters, including tumor grade, nodal positivity, and stage, as well as with adverse clinical outcomes such as overall and disease-free survival. Thus, TIMM17A is a promising diagnostic and prognostic marker for breast cancer patients.
To date, the prognostic significance of TIMM9 expression level in human GC has not been established. This study investigated the correlations between TIMM9 expression and clinicopathologic parameters, and evaluated the significance of TIMM9 in predicting the prognosis for patients with GC.
Materials and methods

Ethics statements
The Institutional Review Board at Wan Fang Hospital, Taipei, Taiwan, approved the tissue acquisition protocol for the immunohistochemical, immunoblotting, and quantitative real-time polymerase chain reaction (PCR) study (Approval Number: 99049). Written informed consent was obtained from each participant before tissue acquisition.
Participants and specimens
The patient cohort comprised 140 consecutive GC cases from 1998 through 2011 documenting pathologic and clinical factors and clinical outcome. All the cases in this study received radical total or subtotal gastrectomy with D2 or D3 lymph node dissection. None of our study patients had received preoperative chemotherapy and/or radiotherapy. The nontumor portion was obtained from grossly normal gastric mucosa, separate from the tumor, in resected gastric specimen. Clinicopathologic parameters of GCs were determined according to the American Joint Committee on Cancer (AJCC) classification. The follow-up duration for disease-free survival was defined as the period between the operation date and the day of relapse, according to the patient's chart. For each patient, we analyzed a pair of tumor and nontumor gastric tissues to determine the TIMM9 expression.
Immunohistochemical analysis
TIMM9 expression was analyzed with immunohistochemistry. Paraffin-embedded tissue blocks were sectioned at 5 mm and transferred to microscope slides (Muto Pure Chemicals Co. Ltd., Tokyo, Japan). The small intestine was used as a positive control for TIMM9. The negative control entailed omission of the primary antibody and incubation with phosphate buffer saline. Sections were dewaxed with xylene and then rehydrated in graded alcohols. Deparaffinized sections were incubated in pH 6.0 citrate buffer for 40 minutes at 95 C on a hotplate to retrieve antigens. Further antigen blocking was performed using Dako REAL Peroxidase-Blocking Solution (Dako North America, Carpinteria, CA, USA) for 5 minutes. The slides were subsequently incubated with primary antibody: mouse monoclonal anti-TIMM9 antibody (Abnova, Taipei, Taiwan, Catalogue Number H00026520-M01, Lot Number E3041-1D6, TIMM9 full-length recombinant protein with glutathione S-transferase tag was used as the antigen) for 1 hour at room temperature, at a dilution of 1:150. Detection of the immunoreactive staining was conducted using the avidinebiotineperoxidase complex method according to the manufacturer's instructions (Dako REAL EnVision Detection System, Dako North AMerica). After incubation with diaminobenzidine for 5 minutes, the sections were counterstained with hematoxylin and mounted in Dako Faramount Aqueous Mounting Medium (Dako North America) for microscopic interpretation. Semiquantitative scoring of intensity (0, no staining; 1, weak staining; 2, strong staining) and fraction of positive cancer cells (0, no staining; 1, less than half; 2, more than half) was undertaken. The final score was calculated for each sample by multiplying the intensity and the percentage of immunostaining: 0, no staining; 1, weak staining; 2, moderate staining; 4, strong staining. Sections with a score of 0 or 1 displayed low expression of TIMM9, whereas those that scored 2 or 4 were defined as having high expression or overexpression of TIMM9. Clinical data collection and immunohistochemical analysis were performed independently of each other, in an investigator-blinded study.
RNA extraction and complementary DNA synthesis
According to the manufacturer's instructions, total RNA from 10 tumor and nontumor pairs of gastric tissues was isolated using an RNA extraction kit (Sigma, St. Louis, MO, USA). RNA quality was analyzed using an Agilent 2100 Bioanalyzer (Agilent, Santa Calra, CA, USA). The values of RNA integrity number of all 20 samples were higher than 7.
Complementary DNA synthesis was performed as described in our previous study. 21 Synthesized complementary DNA was stored at À20 C until use.
Primers and quantitative real-time PCR
Primers of TIMM9 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), an internal control, and real-time PCR master mix were purchased from Sigma. The expression levels of the target genes were measured using quantitative real-time PCR in the Illumina Eco System (Illumina, San Diego, CA, USA). Threshold cycle (C t ) is the fractional cycle number at which the fluorescence generated by cleavage of the probe exceeds a fixed level above baseline. For a chosen threshold, a smaller starting copy number results in a higher C t value. The amount of TIMM9 messenger RNA (mRNA) in tumor or nontumor tissues, standardized against the amount of GAPDH mRNA, was expressed as DC tumor or DC nontumor Z C t (TIMM9) e C t (GAPDH) . 
Cell culture
Total protein preparation
Total proteins were extracted using M-PER Mammalian Protein Extraction Reagent and T-PER Tissue Protein Extraction Reagent (Pierce Biotechnology, Rockford, IL, USA), according to the manufacturer's instructions. The samples were stored at À80 C until used. The protein concentration was determined using a BCA Protein Assay Kit (Pierce Biotechnology) with bovine serum albumin as a standard.
Immunoblotting
Denatured protein samples were subjected to 18% sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins were transferred to nitrocellulose membranes, and blocked blots were incubated at 4 C overnight with anti-TIMM9 polyclonal antibody (1:100 dilution). GAPDH was used as an internal control for equal protein loading (mouse monoclonal anti-GAPDH antibody was purchased from Millipore, Billerica, MA, USA; Catalogue Number MAB374, Lot Number JC1682928, GAPDH from rabbit muscle was used as the antigen). Blots were further incubated with secondary antibodies conjugated with peroxidase (Sigma) for 1 hour at room temperature. They were then incubated with Western Lighting ECL Pro Chemiluminescence Substrate (PerkinElmer, Waltham, MA, USA), and exposed to a Fuji medical x-ray film (Fuji Photo Film Co., Tokyo, Japan). Image processing was performed using Fuji Image Gauge software. Short hairpin RNA treatment
For short hairpin RNA treatment, AGS cells were infected with lentiviral vectors (one TIMM9-short hairpin RNA construct, clone identification: TRCN0000151300 and one control, clone identification: pLKO_TRC025, purchased from the National RNAi Core Facility, Taipei, Taiwan) and stable clones resistant to puromycin (Santa Cruz, Dallas, TX, USA) were selected.
In-vitro invasion assay
The cell invasion capability was examined using a Cell Invasion Assay Kit (Merck Millipore, Darmstadt, Germany), following the manufacturer's instructions. Complete media were first added to 24-well plates. The cells (2 Â 10 5 ) in serum-free media were added to ECMatrix-layered cell culture inserts (containing 8-mm pore size polycarbonate membranes) and cultured for 24 hours. Before staining, the cells on the upper surface were removed. Inserts were then dipped in the staining solution to stain invaded cells on the lower surface of the membranes. The cultures were photographed (100Â magnification, with Leica DMIRB microscope, Leica, Wetzlar, Germany).
Statistical analysis
Paired t tests were used to assess the difference in TIMM9 expression between tumor and nontumor tissues for each patient. We examined several clinicopathologic parameters: age, sex, depth of invasion, nodal status, distant metastasis, stage, degree of differentiation, and vascular permeation. The correlation between TIMM9 expression and each clinicopathologic parameter was examined using c 2 test. The time-to-event endpoints for all clinicopathologic parameters were plotted using the KaplaneMeier method, and the degree of significance was calculated using the univariate log-rank test. p < 0.05 was considered significant. Parameters that emerged as significant (p < 0.05) in the univariate analysis were entered as variables in the multivariate Cox regression model, and hazard ratio (HR) and independence of prognostic impact were determined in a stepwise backward fashion. All data were analyzed using SPSS software version 17.0 (SPSS, Chicago, IL, USA).
Results
Basic data
This study enrolled 140 patients with GC; 91 of the 140 patients were men and 49 of the 140 patients were women (Supplementary Table 1 ). The patients' ages ranged from 34 years to 96 years at first diagnosis (mean, 69.2 years). Based on the AJCC classification, 29 patients were at Stage I, 34 were at Stage II, 62 were at Stage III, and 15 were at Stage IV. The follow-up period for all patients ranged from 0 months to 141.3 months (mean, 29.5 months). Eightyeight patients died during follow-up.
TIMM9 expression was upregulated and associated with vascular invasion in GC
We used immunohistochemical analysis to investigate the expression of TIMM9 in tissues obtained from our study patients ( Figures 1A and 1B) . TIMM9 expression was significantly higher in tumor tissues than in nontumor tissues (p < 0.001). Overexpression of TIMM9 (scores of 2 or 4) was observed in 54 of the 140 patients (38.6%). In addition, quantitative real-time PCR analysis demonstrated that the expression of TIMM9 mRNA was substantially increased in tumor tissues compared with nontumor tissues (Table 1, Figure 2A ). Immunoblotting analysis also demonstrated that the expression of TIMM9 was substantially increased in GC cells and tissues compared with normal cells and tissues ( Figure 2B ). As shown in Table 2 , overexpression of TIMM9 was associated with vascular invasion with a borderline significance (p Z 0.0887). TIMM9 was knocked down in AGS cells to further support the data from immunohistochemical analysis. As shown in Figure 3 , inhibiting TIMM9 decreased AGS cell invasion. No significant association was found between the overexpression of TIMM9 and other clinicopathologic parameters.
Overexpression of TIMM9 as a prognostic marker for GC
Correlations of clinical outcomes with TIMM9 expression are shown in Figure 4 . Overexpression of TIMM9 was significantly associated with inferior disease-free survival ( Figure 4A ; p Z 0.005). Five-year disease-free survival rate in patients with high expression levels of TIMM9 was of 27.6%, whereas that in patients with low expression levels was 56.6%. Because the tumor stage is a critical prognostic marker of GC, low-stage (Stage I and II) and high-stage GC (Stage III and IV) were used independently to determine the effect of TIMM9 overexpression on the prognosis. We found that in high-stage GC, shorter disease-free survival was significantly associated with overexpression of TIMM9 ( Figure 4B ; p Z 0.040). However, in low-stage GC, the association between overexpression of TIMM9 and diseasefree survival was only borderline significant ( Figure 4C ; p Z 0.066).
The results of univariate analysis of the prognostic markers of GC are presented in Table 3 . Disease-free survival was significantly correlated with each of the following: overexpression of TIMM9 (p Z 0.007), depth of invasion (p < 0.001), nodal status (p < 0.001), distant metastasis (p < 0.001), stage (p < 0.001), degree of differentiation (p Z 0.014), and vascular invasion (p < 0.001). Table 1 was plotted; (B) TIMM9 protein expression was examined in five gastric cells and two tumor and nontumor pairs of gastric tissues. GAPDH Z glyceraldehyde-3-phosphate dehydrogenase. The association between overexpression of TIMM9 and survival was significant even after controlling for other well-known prognostic markers in multivariate analysis (Table 4) . In multivariate analysis, overexpression of TIMM9 (HR Z 0.531, 95% confidence interval Z 0.325e0.867, p Z 0.011) and distant metastasis (HR Z 0.133, 95% confidence interval Z 0.052e0.336, p < 0.001) were prognostically independent.
Discussion
Surgical resection is generally considered the best treatment to improve the prognosis when early diagnosis of GC is successful. 22 Unfortunately, most cases of GC are diagnosed at a locally advanced stage. To develop novel strategies to prevent and treat GC, a comprehensive understanding of the molecular mechanisms underlying the development of this deadly neoplasm is essential. In particular, identification of the molecules altered during cancer progression can provide valuable tools as prognostic markers or therapeutic targets.
Mitochondria have an established role in cell proliferation. In keeping with this, an emerging role of mitochondria in carcinogenesis is supported by an increasing body of evidence. 23 Mitochondrial function is profoundly dependent on the import of cytosolic proteins, and defects in the translocation system can result in significant functional impairment. Mitochondrial dysfunction has been shown to promote the development of several human malignancies. 24 The expression of mitochondrial protein TIMM9 in human cancers varies according to cancer type. The survey of a public human protein atlas database indicated that TIMM9 protein level is elevated in numerous human cancers, including thyroid, lung, and liver cancer, whereas it is decreased in pancreatic cancer. Our literature review identified only one study, by Wang et al, 25 that investigated the expression of TIMM9 in human GC. This study revealed that TIMM9 protein expression level was not increased in patients with GC. The failure to reach a significant difference between tumor and nontumor gastric tissues may be due to the small sample size (only 12 tumor/nontumor paired tissues were analyzed). In the present study, we assessed the expression levels of TIMM9 in gastric tissues obtained from 140 GC patients. The results of our study were inconsistent with those of Wang et al 25 and suggested that TIMM9 expression was elevated in gastric tumor tissues compared with nontumor gastric tissues. The immunoblotting results confirmed that TIMM9 expression was higher in GC tissues and cells than in normal gastric tissues and cells.
Statistical analysis suggested that overexpression of TIMM9 in GC tissues was closely correlated with vascular invasion. Data from in vitro cell invasion assay further support this correlation. However, the reason for this relationship between TIMM9 overexpression and vascular invasion remains unclear. The only one line of evidence comes from the studies conducted by Ishikawa et al 26 and Du et al. 27 Ishikawa and her colleagues 26 treated the high-metastatic mouse tumor cells with reactive oxygen species (ROS) scavengers and examined their effects on the amounts of ROS and their metastatic ability. The results indicated that the intracellular amount of ROS will affect their metastatic potential in mouse model. 26 However, Du et al 27 showed that arsenic treatment results in increased intracellular levels of ROS and TIMM18 in yeast. Their results also suggested that TIMM18 probably acted downstream of ROS formation. Direct evidence for the relationship between TIMM18 and metastasis are still insufficient. Furthermore, whether the reason for TIMM9 is the same as that of TIMM18 also warrants investigation.
Precise prediction of the risk of recurrence of GC would assist in minimizing the adverse effects and maximizing the therapeutic effect of the treatment. Of the available prognostic markers for GC, the AJCC stage is most important. However, the prognosis varies even among patients at the same disease stage; hence, alternative prognostic markers for GC are required. Mitochondrial markers have been intensively pursued in recent years. Wang et al 25 demonstrated that in GC patients, a strong association existed between increased inhibin beta A (INHBA) expression and poor patient survival. Similarly, Wang et al 25 showed that overexpression of CISD2 protein was an independent poor prognostic marker for GC. 28 In addition, studies by both Xu et al 18 and Salhab et al 20 indicated that a strong association existed between increased TIMM17A expression and poor patient survival in cases of GC. The role of TIMM9 in tumor prognosis is still unknown. The results of this study indicated that TIMM9 overexpression was inversely correlated with patient survival. Our study was the first to report that overexpression of TIMM9 can predict poorer outcomes for patients with GC. Overexpression of TIMM9 appears to be a useful marker to predict outcomes in patients with GC who have received surgical resection of the tumor. Thus, patients with GC who display overexpression of TIMM9 should be followed-up carefully.
The limitations of this study include the small sample size for the GC cohort. Accordingly, additional cohort studies would be helpful to confirm our findings.
In summary, this study provides evidence for the clinical significance of overexpressed TIMM9 in patients with GC. Our findings indicate that targeting TIMM9 might provide a new therapeutic modality for the treatment of GC.
